ALN-6400

Phase 2Small molecule

Alnylam Pharmaceuticals

ALN-6400 is one of 2 small molecule programs targeting Von Willebrand Disease (VWD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand Disease (VWD)Recruiting

Von Willebrand Disease (VWD)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Von Willebrand Disease (VWD)

#DrugCompanyPhaseTrials

VGA039

VVega Therapeutics, Inc

Phase 3

1 2

ALN-6400

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalActive, not recruiting

Hereditary Hemorrhagic Telangiectasia

NCT06659640

Q4 2028

Phase 2Recruiting

Von Willebrand Disease (VWD)

NCT07575308

Clinical

Trials by Indication[1]

Von Willebrand Disease (VWD)1 trial

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 2·NCT07575308·24 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Active, not recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Preclinical·NCT06659640·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALN-6400. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-6400 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-6400. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Alnylam Pharmaceuticals

ALN-6400

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Von Willebrand Disease (VWD)1 trial

Hereditary Hemorrhagic Telangiectasia1 trial

References

Drug Info

Quick Facts

Related News